Filing Details

Accession Number:
0001493152-22-009000
Form Type:
4
Zero Holdings:
No
Publication Time:
2022-04-04 16:05:36
Reporting Period:
2022-03-31
Accepted Time:
2022-04-04 16:05:36
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
876343 Lineage Cell Therapeutics Inc. LCTX Biological Products, (No Disgnostic Substances) (2836) 943127919
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1310683 M Brian Culley 2173 Salk Avenue, Suite 200
Carlsbad CA 92008
President And Ceo Yes Yes No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Shares, No Par Value Acquisiton 2022-03-31 15,450 $0.00 96,730 No 4 M Direct
Common Shares, No Par Value Disposition 2022-03-31 5,343 $1.54 91,387 No 4 F Direct
Common Shares, No Par Value Acquisiton 2022-03-31 6,400 $1.53 97,787 No 4 P Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 M Direct
No 4 F Direct
No 4 P Direct
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Shares Restricted Stock Units Disposition 2022-03-31 15,450 $0.00 15,450 $0.00
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
15,450 No 4 M Direct
Footnotes
  1. Shares earned by the reporting person as a result of the vesting of a portion of restricted stock units ("RSUs") granted to the reporting person on September 17, 2018. RSUs convert into common shares on a one-for-one basis.
  2. Does not include RSUs that may be settled in shares of the issuer's common stock that have not vested as of the date of this report or shares that may be acquired upon the exercise of stock options outstanding as of the date of this report.
  3. Shares withheld by the issuer to satisfy statutory tax withholding requirements on the vesting of RSUs in a transaction exempt under Rule 16(b)-3. No shares were sold in connection with this transaction.
  4. The price reported is a weighted average. The shares were purchased in multiple transactions at prices ranging from not less than $1.52 to not more than $1.54. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within such range.
  5. The reporting person was granted RSUs on September 17, 2018, that vested with respect to 25% of the shares subject to the award on September 17, 2019, and the balance vest in 12 equal quarterly installments at the end of each quarter thereafter.